Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT00948064. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
ClinicalTrials.gov study NCT03298984. IPD Sharing: NO. Countries: 1. Publications: 1.
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
ClinicalTrials.gov study NCT00952588. IPD Sharing: Not stated. Countries: 9. Publications: 1.
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT01261312. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
ClinicalTrials.gov study NCT02921061. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
ClinicalTrials.gov study NCT02348489. IPD Sharing: Not stated. Countries: 24. Publications: 1.
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
ClinicalTrials.gov study NCT02421939. IPD Sharing: YES. Countries: 14. Publications: 4.
Natural Killer (NK) Cell Transplantation for AML
ClinicalTrials.gov study NCT00187096. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of FMT in Patients With AML Allo HSCT in Recipients
ClinicalTrials.gov study NCT03678493. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
ClinicalTrials.gov study NCT00887068. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
ClinicalTrials.gov study NCT03068819. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT01074047. IPD Sharing: Not stated. Countries: 18. Publications: 2.
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
ClinicalTrials.gov study NCT00049517. IPD Sharing: Not stated. Countries: 2. Publications: 10.
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
ClinicalTrials.gov study NCT05184842. IPD Sharing: NO. Countries: 1. Publications: 1.
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for In
ClinicalTrials.gov study NCT02472145. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Nivolumab in AML in Remission at High Risk for Relapse
ClinicalTrials.gov study NCT02532231. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
ClinicalTrials.gov study NCT04801797. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00890929. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
ClinicalTrials.gov study NCT00088218. IPD Sharing: Not stated. Countries: 1. Publications: 1.
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT01038635. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.